Skip to main content

Aripiprazole in bipolar disorder: clinical strategies to maximize efficacy and tolerability

A number of double-blind, randomized, controlled trials have confirmed the clinical efficacy of aripiprazole in bipolar disorder and schizophrenia. Aripiprazole is the prototype of the 'third generation' atypical antipsychotics, or dopamine-serotonin- stabilizers and is characterized by a relatively low risk of inducing metabolic adverse effects, causing sedation and other side effects such as hyperprolactinemia. As a partial agonist at dopamine D2 receptors, aripiprazole acts as a functional antagonist in the mesolimbic dopamine pathway, where excessive dopamine activity is thought to cause positive symptoms, but acts as a functional agonist activity in the mesocortical pathway, where reduced dopamine activity is thought to be associated with negative symptoms and cognitive impairment. This presentation will review the available research data on the efficacy of aripiprazole in bipolar disorder and discuss how this data translate in the real world clinical practice and what the best strategies are to maximize the efficacy and tolerability of this medication.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Andrea Fagiolini.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Fagiolini, A. Aripiprazole in bipolar disorder: clinical strategies to maximize efficacy and tolerability. Ann Gen Psychiatry 9, S60 (2010). https://doi.org/10.1186/1744-859X-9-S1-S60

Download citation

Keywords

  • Dopamine
  • Schizophrenia
  • Bipolar Disorder
  • Negative Symptom
  • Aripiprazole